Adjuvant chemotherapy on survival of patients with stage IB non‑small cell lung cancer: a comparison study with propensity score matching

Author:

Yang Xinyu,Han Guang,Hu Yunfan,Ren Changhao,Zhao Mengnan,Jiang Tian,Feng Mingxiang,Li MingORCID

Abstract

Abstract Background This study aimed to investigate whether patients with stage IB NSCLC could benefit from adjuvant chemotherapy. Methods In the years 2010 to 2015, 1,829 NSCLC patients with stage IB disease were chosen from the SEER database. To equalize the baseline characteristics between the surgery plus adjuvant chemotherapy group (intervention) and the surgery alone group (control), propensity score matching (PSM) was used. The log-rank test plotted Kaplan–Meier survival curves to compare the overall survival (OS) and disease-specific survival (DSS). Cox proportional hazard regression was used to perform univariate and multivariate analysis on overall survival. Results One hundred ninety-seven patients in each group with a mean follow-up period of 65.4 months were enrolled after PSM. A significant benefit in overall survival ([intervention vs. control] HR = 0.72; 95% CI: 0.54 to 0.94; P = 0.026) was detected in the intervention group before PSM. And there were significantly improved OS (HR = 0.63; 95% CI: 0.42 to 0.92; P = 0.036) and DSS (HR = 0.73; 95% CI: 0.52 to 0.95; P = 0.044) for the patients with visceral pleural invasion (VPI) in the intervention group compared with the control group. After PSM, the patients with VPI in the intervention group had better overall survival (HR = 0.69; 95% CI: 0.40 to 0.98; P = 0.048) than those in the control group. The Cox proportional hazard regression analysis showed that VPI (HR = 1.29; 95% CI: 1.11 to 1.54; P < 0.001) was also an independent prognostic factor. Conclusion Stage IB NSCLC with VPI could benefit from adjuvant chemotherapy after R0 resection.

Funder

National Natural Science Foundation of China

National Postdoctoral Innovation Talents Support Program of China

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3